Construction tracker sizes the GLP-1 building boom around Lilly's sites

A new report from Industrial Info Resources, a firm that tracks industrial construction projects, put specific numbers on how much money Eli Lilly is spending to build out factories for its GLP-1 drugs. The report says Lilly is investing more than $13 billion at its Lebanon, Indiana campus, part of a broader wave of pharmaceutical construction the firm says is being driven by demand for GLP-1 medicines ^[1].

The Lebanon figure covers a range of products beyond GLP-1 drugs, but the report says GLP-1 medicines are a major part of the plan ^[1]. Outside Indiana, the tracker counted $3.2 billion of Lilly construction currently underway abroad, with another $3.7 billion in planning or engineering stages ^[1]. One of the largest planned foreign projects is an oral-dose GLP-1 plant in the Netherlands, budgeted at roughly $1.5 billion to start, with the possibility that spending could double later ^[1].

Several of the projects tracked by the firm are tied specifically to orforglipron, Lilly's experimental oral GLP-1 drug that has not yet been approved by regulators. A project in Houston, Texas will make small-molecule active ingredients for oral GLP-1 drugs still awaiting approval ^[1]. In Puerto Rico, a building addition just broke ground and is expected to start contributing to oral-dose GLP-1 production in 2029 ^[1]. Lilly is also planning a $6 billion new campus in Huntsville, Alabama that includes orforglipron in its scope ^[1]. Separately, a seven-building campus in Fogelsville, Pennsylvania is tied to the injectable drugs Zepbound and Mounjaro, plus the experimental drug retatrutide ^[1].

The construction tracker's numbers sit alongside a separate figure from Lilly itself. In a statement covered by Scientist Live, Lilly said it will more than double its U.S. manufacturing investment since 2020, surpassing $50 billion total, through four new U.S. plants — three focused on active ingredients and one on injectable drug production ^[2]. That total includes $23 billion in commitments Lilly already made between 2020 and 2024, on top of the new sites ^[2]. Lilly says the buildout could create more than 3,000 permanent jobs and nearly 10,000 construction jobs ^[2]. The two sources track spending differently — one counts specific tracked construction projects, the other is a company-wide manufacturing investment tally — so the totals are not directly comparable.

The construction boom is not limited to Lilly. The same tracker noted Novo Nordisk, maker of Ozempic and Wegovy, is investing $4.1 billion more at its Clayton, North Carolina campus and has $9.1 billion in construction underway outside the U.S. ^[1].

Why it matters for patients

This is a story about factories, not about drug prices or availability changing this week. But the scale of construction gives a sense of how much manufacturers expect demand for GLP-1 drugs to grow, and how central oral pills like orforglipron are to that bet. A Gallup poll cited in the report found 11% of U.S. adults reported taking a GLP-1 drug for weight loss in 2026, up from 3% in 2024, which helps explain why companies are building at this scale ^[1].

For patients specifically interested in oral GLP-1 options, the timeline matters: the Puerto Rico facility tied to oral-dose production isn't expected to contribute until 2029, and the Houston site is described as producing ingredients for oral drugs "still needing regulatory authorization," meaning orforglipron has not yet cleared approval ^[1]. None of the sources say when orforglipron might be approved or reach pharmacies.

What happens next

The Puerto Rico building addition is expected to begin contributing to oral-dose GLP-1 production in 2029 ^[1]. No specific completion dates were given for the Houston, Huntsville, or Netherlands projects in the sources provided. Regulatory approval status for orforglipron in the U.S. is not addressed in these sources and is not yet known from this reporting.